Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sajjad A Bhatti

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Cancer Immunology, Immunotherapy : CII|September 29, 2025
Efficacy and safety of two-year fixed versus continuous immune checkpoint inhibitor therapy in advanced or metastatic non-small cell lung cancer: a systematic reviewToshali Pandey, Sajjad A Bhatti
Cancers|March 10, 2022
Immune Checkpoint Inhibitors-Associated CardiotoxicityChenghui Li, Sajjad A Bhatti, Jun Ying
JCO Oncology Practice|September 20, 2023
Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non-Small-Cell Lung Cancer and Synchronous Brain MetastasesRuchira Mahashabde, Sajjad A Bhatti, Bradley C Martin, et al.
Translational Lung Cancer Research|August 9, 2024
Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastasesRuchira V Mahashabde, Sajjad A Bhatti, Bradley C Martin, et al.
Current Oncology (Toronto, Ont.)|September 26, 2025
Survival Outcomes of Immune Checkpoint Inhibitors in Conjunction with Cranial Radiation for Older Adults with Non-Small Cell Lung Cancer and Synchronous Brain MetastasisRuchira V Mahashabde, Sajjad A Bhatti, Bradley C Martin, et al.
Cancers|July 27, 2022
Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to BenchShi-Ming Tu, Sunny R Singh, Konstantinos Arnaoutakis, et al.
Cancers|March 28, 2024
Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer CareShi-Ming Tu, Anup K Trikannad, Sruthi Vellanki, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Cancer Immunology, Immunotherapy : CII|September 29, 2025
Efficacy and safety of two-year fixed versus continuous immune checkpoint inhibitor therapy in advanced or metastatic non-small cell lung cancer: a systematic reviewToshali Pandey, Sajjad A Bhatti
Cancers|March 10, 2022
Immune Checkpoint Inhibitors-Associated CardiotoxicityChenghui Li, Sajjad A Bhatti, Jun Ying
JCO Oncology Practice|September 20, 2023
Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non-Small-Cell Lung Cancer and Synchronous Brain MetastasesRuchira Mahashabde, Sajjad A Bhatti, Bradley C Martin, et al.
Translational Lung Cancer Research|August 9, 2024
Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastasesRuchira V Mahashabde, Sajjad A Bhatti, Bradley C Martin, et al.
Current Oncology (Toronto, Ont.)|September 26, 2025
Survival Outcomes of Immune Checkpoint Inhibitors in Conjunction with Cranial Radiation for Older Adults with Non-Small Cell Lung Cancer and Synchronous Brain MetastasisRuchira V Mahashabde, Sajjad A Bhatti, Bradley C Martin, et al.
Cancers|July 27, 2022
Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to BenchShi-Ming Tu, Sunny R Singh, Konstantinos Arnaoutakis, et al.
Cancers|March 28, 2024
Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer CareShi-Ming Tu, Anup K Trikannad, Sruthi Vellanki, et al.
Pageof 1